GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | GRI Stock NewsStockTitan·1 day ago, 12:05 AMGRI+9.50%
GRI Bio, Inc. 2Q 2026: Net income $(1.64) M, EPS $(0.91) — 10-Q SummaryTradingView·Aug 14 at 06:51 AMGRI+9.50%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Aug 11 at 12:06 PMALMR+0.98%GRI+9.50%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jul 20 at 07:05 AMBRNS+9.43%VBIO-4.22%
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | GRI Stock NewsStockTitan·Jun 17 at 11:31 PMGRI+9.50%
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Knowbenzinga_article·Jun 1 at 07:43 AMOCS-1.67%NDRA+4.17%
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase | GRI Stock NewsStockTitan·May 18 at 12:15 AMGRI+9.50%SBIO+2.46%
GRI Bio Highlights Promising Phase 2a IPF Data, OutlookTip Ranks·May 14 at 08:02 AMGRI+9.50%XBI+3.00%
